Peer Review History
| Original SubmissionFebruary 15, 2020 |
|---|
|
PONE-D-20-03806 Acute Renal Failure in Children. Multicenter Prospective Cohort Study in Medium Complexity Intensive Care Units from the Colombian Southeast PLOS ONE Dear Dr. Forero, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses all the critical points raised during the review process by the two reviewers. We would appreciate receiving your revised manuscript by Apr 27 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Emmanuel A Burdmann Academic Editor PLOS ONE Journal Requirements: Journal Requirements: When submitting your revision, we need you to address these additional requirements: 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf and http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for including your ethics statement: 'This study was approved by the ethics committees at the four institutions (Resolution 301 of May 2013 and Resolution 0665 of 19 October 2011).' (a) Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study. (b) Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”). For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research. 3. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. 4. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) the recruitment date range (month and year) and b) a description of how participants were recruited. 5. Please provide a sample size and power calculation in the Methods, or discuss the reasons for not performing one before study initiation. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: No Reviewer #2: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This is an interesting study whose objective was to estimate the incidence and prognosis of AKI, associated complications and mortality, in medium-complexity PICUs from the Colombian southeast using KDIGO classification. The title and abstract are clear. In the introduction the AKI definition ‘ Acute kidney injury (AKI) is a pathology defined as a sudden loss of the renal function that can be reversible.” should be changed to “Acute kidney injury (AKI) is a syndrome, defined by a rapid increase in serum creatinine decrease in urine output, or both”, (Lancet 2019; 394: 1949–64), its reversibility should not be included in the definition Methodology and Statistical analysis are well described. Results are very difficult to interpret: The text states that “ stage I (mild) was diagnosed in 2.5% of total admissions (52 patients), stage II (moderate) in 1.6% (34 patients), and stage III (severe) in 1.1% (24 patients). Seventy eight patients (71%) reached their maximum KDIGO stage on the first day from the admission to PICU Commentary: These percentages should be calculated in relation to the 110 patients diagnosed with AKI and not in relation to the total screened admissions Table 1 shows that 90 patients (81.8% were classified as pre-renal AKI 20 (18.2%) as renal AKIl Commentary: based on the list of primary diseases this information is probably inaccurate In the methodology session Severe acute kidney injury corresponded to patients classified as KDIGO 2 and 3 The results session states that “Severe AKI developed in 58 patients (2.7%; 95%CI 2.1 to 3.5). information that is also on table 2 but the results description continues as follows “ The severity classification according to KDIGO was 25 patients (22.7%) in stage 1, 40 patients (36.4%) in stage 2 and 45 patients (40.9%) in stage 3, severe AKI affected in fact 40+45= 85 patients Commentary: the authors should review their definitions and review the tables as well as the rest of the text The phrase “On average, the severe stage of AKI was higher in non-survivors than in survivors” could be written as “The mortality rate for patients with severe AKI was higher than in the mild /moderate cases. The other parameters such as length of stay, mechanical ventilation and RRT could have their relation to AKI re-phrased in the same way English language should be revised throughout the text The authors conclusions are in consonance with the literature but patient characteristics differ from the ones previously described in developed countries, the patients described in this study were admitted to medium complexity PICUs, mostly with medical primary diseases , 71% of the patients had their maximum KDIGO on day one of admission, so the diagnosis of AKI was probably late ( is it due to lack of hospital facilities in the Colombian rural area??) and probably related to disorders of volume status and infection , almost 40% of them were presented malnutrition or were at risk of this comorbidity, My suggestion would be for the authors to describe these characteristics in more detail and the efforts that should be developed to minimize them Reviewer #2: The authors conducted a prospective, observational study to assess the incidence and prognosis of AKI in PICUs of southeast Colombia. They found a cumulative incidence of AKI of 5.2% and that AKI was associated with worse clinical outcomes. The study will improve the knowledge of the local epidemiology of AKI in Colombia, but will not have any impact on the knowledge of what is already know about AKI and outcomes in pediatric population. I have some comments, and observations that the authors need to address: 1. I would recommend avoiding abbreviations on the abstract, and if used please define them (i.e. KDIGO). 2. Authors need to exclude from their analysis patients would were diagnosed with AKI at ER, and only include patient that developed AKI during PICU stay, the reasoning for this is that some % of patients with AKI diagnosis at ER could have non-diagnosed CKD, could be with AKD, or have community acquired AKI and this different type of populations have different risk for several short and long-term outcomes. 3. Why do authors exclude patients with CKD? Since CKD is an important risk factor for subsequent AKI and could affect outcomes? 4. How you deal with the fact that some patients did not had baseline serum creatinine? You used urine volume criteria? You used MDRD <60 ml/m/1.73m2 to estimate baseline sCr? 5. On table one; how you were able to differentiate patients with intrinsic renal damage from those who have Pre-renal? Please clarify. What do you refer that 18% of patients have “renal classification of AKI” this is not clear. 6. On page 8 you said that 58 patients developed severe AKI, however you later said that 45 patients developed stage 3 of AKI is that not consider severe AKI too? You need to check your numbers . 7. You need to show fluid balance of your patients, fluid overload is an important contributing factor for adverse outcomes: Fluid overload should be assessed as % increase of body weight, Bouchard et al have shown that patients with fluid overload defined as an increase in body weight of over 10% had significantly more respiratory failure, need of mechanical ventilation, and more sepsis. Please review and use this definition for fluid overload: Percentage of fluid overload adjusted for body weight: cumulative fluid balance that is expressed as a percent. A cutoff of ≥10% has been associated with increased mortality. Fluid overload percentage can be calculated using the following formula: % Fluid overload = ((total fluid in – total fluid out)/admission body weight x 100) Authors should stratified each group of patients in < 10% of fluid overload, 11% to 20% of fluid overload, > 20% of fluid overload for example, in order to assess for adverse outcomes. Review this study: Bouchard J, Mehta RL. Fluid balance issues in the critically ill patient. Contrib Nephrol. 2010;164:69-78. 8. What was the mean or median of fluid received during PICU stay? Would like to see fluids that were given by oral route and by I.V. 9. I recommend also that authors need to look at factors that could have influence on having prolonged mechanical ventilation like sepsis, comorbidities (i.e. chronic illness), nutrition and metabolic problems, cardiovascular disease, pneumonia, and ventilation modality. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Vera H. Koch Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-20-03806R1 Acute Renal Failure in Children. Multicenter Prospective Cohort Study in Medium Complexity Intensive Care Units from the Colombian Southeast PLOS ONE Dear Dr. FORERO, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 17 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Emmanuel A Burdmann Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The revised manuscript shows improvements in relation to the previous one Title, abstract and introduction are clear Methodology: the term creatinine serum has to be substituted by serum creatinine Results: where it says " No significant association was noted for gender, age, primary diagnosis, and nutritional status with the presence of severe AKI (Table 2" it should say No significant association was noted for gender, age, primary diagnosis, and nutritional status with the presence of severe AKI (Table 1) Table 2 is confusing as it classifies the patients into mild/moderate and severe AKI and all the p values are non significant , but the text follows with a paragraph where it is clear that the significant differences were mainly between KDIGO 1 and 3 patients, so table 2 has to be modified and present data classified according to KDIGO status 1, 2 and 3, incorporating all the significant p values shown in the following paragraphs Discussion is much improved and shows the importance of the presented data to Latin America The text still needs an English language revision Reviewer #2: (No Response) ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Vera Koch Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Acute Renal Failure in Children. Multicenter Prospective Cohort Study in Medium Complexity Intensive Care Units from the Colombian Southeast PONE-D-20-03806R2 Dear Dr. Forero, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Emmanuel A Burdmann Section Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: (No Response) ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: (No Response) ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: (No Response) ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: (No Response) ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Vera Koch |
| Formally Accepted |
|
PONE-D-20-03806R2 Acute Renal Failure in Children. Multicenter Prospective Cohort Study in Medium-Complexity Intensive Care Units from the Colombian Southeast Dear Dr. Forero-Delgadillo: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Emmanuel A Burdmann Section Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .